 |
|
Serum Uric Acid and Clinical Progression in Parkinson DiseasePotential Biomarker for Nigrostriatal Failure
Mya Schiess, MD;
Irene Oh, MD
Arch Neurol. 2008;65(6):698-699.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Parkinson disease (PD) is the second most common neurodegenerative disorder, with a prevalence and incidence rate that increases significantly with age. In North America, an estimated 1% of the population older than 65 years has PD. During the past decade, our understanding of this disease has been radically transformed, particularly regarding its neuropathology, molecular biology, and genetics. Nonetheless, PD remains clinically defined, using the comprehensive neurological examination as the gold standard and clinical measures such as the Unified Parkinson Disease Rating Scale (UPDRS) and the Hoehn & Yahr (H&Y) disability staging to confirm diagnosis and to assess disease progression.1-2
Biological markers for PD that can serve as surrogates for clinical measures have remained elusive. In this issue of Archives of Neurology, Schwarzschild and colleagues3 explore the potential of serum uric acid (UA) as a biomarker of clinical progression in PD. Their prospective, longitudinal . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED ARTICLES
Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
Michael A. Schwarzschild, Steven R. Schwid, Kenneth Marek, Arthur Watts, Anthony E. Lang, David Oakes, Ira Shoulson, Alberto Ascherio, and and the Parkinson Study Group PRECEPT Investigators
Arch Neurol. 2008;65(6):716-723.
ABSTRACT
| FULL TEXT
This Month in Archives of Neurology
Arch Neurol. 2008;65(6):695-697.
FULL TEXT
|
